 | |
| Names | |
|---|---|
| Preferred IUPAC name 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C20H25N3O4 | |
| Molar mass | 371.437 g·mol−1 |
| Pharmacology | |
| J01MB08 ( WHO ) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Nemonoxacin is a non-fluorinated quinolone antibiotic undergoing clinical trials. [1] It has the same mechanism of action as fluouroquinolones; it inhibits DNA gyrase, preventing DNA synthesis, gene duplication, and cell division. At the end of 2016, it had reached market in Taiwan, Russia, the Commonwealth Independent States, Turkey, mainland China, [2] and Latin America [3] under the brand name Taigexyn. Nemonoxacin has completed phase 2 trials in the US and has moved on to phase 3 trials. [4] The U.S. Food and Drug Administration (FDA) has granted nemonoxacin qualified infectious disease product (QIDP) and fast track designations for community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin-structure infections (ABSSSI). [5]
Nemonoxacin has a broad spectrum of activity against Gram-positive, Gram-negative, and atypical pathogens, including activity against methicillin-resistant Staphylococcus aureus (MRSA) (MIC90 1 g/ml) and vancomycin-resistant pathogens. [6] [7] However, it was less active against Gram-negative pathogens such as Escherichia coli, Proteus mirabilis , and Pseudomonas aeruginosa , with MIC90 values of 32, 16, and 32 g/ml, respectively. [8] The new drug also is effective against C.difficile isolates that are resistant to other quinolones, [9] and is more potent than levofloxacin or moxifloxacin. [10]